Hematologyandoncology.net

Evolving Standards Of Care For Neoadjuvant And Adjuvant

Patients were categorized as PET responders if their tumor demonstrated a decrease of at least 35% in standard uptake value (SUV) from baseline. If patients were classified as PET responders, they ­continued chemoradiation therapy (radiation at 50.4 Gy in 28 fractions) and the same chemotherapy regimen they had received during induction therapy.

Actived: Thursday Jan 1, 1970

View Details Hematologyandoncology.net

Rituximab Plus Bendamustine for the Treatment of ...

Posted: (52 years ago) PET-CT showed bulky fluorodeoxyglucose (FDG)-avid disease in the abdomen, with additional uptake in the liver, bone, and lung. Mrs. S. began treatment with rituximab 375 mg/m 2 and bendamustine 90 mg/m 2 on days 1 and 2. By day 17, her bilirubin was normal, serum AST and ALT were 92 mg/dL

Treat View Details

Monitoring Lymphoma Patients After Therapy – …

Posted: (52 years ago) PET scans were developed to have better sensitivity for aggressive lymphomas than CT scans, and that appears to be true. However, the increased sensitivity comes at the cost of less specificity, and they also have been unable to affect clinical outcomes when used during or after therapy in patients with DLBCL.

Pet View Details

Excessive Therapeutic Response in a Case of Blastic ...

Posted: (52 years ago) Positron emission tomography (PET)/computed tomography (CT) scans indicated complete response after the eighth cycle. However, in August 2009, while evaluation for stem cell transplantation was being arranged, he again developed similar extensive cutaneous lesions over his face, scalp, trunk, and extremities (Figure 1, top panel).

Pet View Details

Hematuria—A Rare Presentation of Hodgkin Lymphoma ...

Posted: (52 years ago) A PET scan is especially useful in determining whether or not a bladder lymphoma is truly “primary,” and it is superior to CT scans for staging and assessing disease extension in both HL and NHL. 9. Morphologic study of the lymph nodes and bone marrow specimens should look for Reed-Sternberg cells, and immunohistochemical studies must also ...

Pet View Details

The Role of AR-V7 Testing in the Management of Metastatic ...

Posted: (52 years ago) We expect eventually to use prostate-specific membrane antigen positron emission tomography (PSMA-PET) to evaluate who is a candidate for 177 Lu-PSMA-617 treatment. Radiopharmaceuticals such as 177 Lu-PSMA-617 and radium-223 are not dependent on AR-V7 testing, and AR-V7 testing is not needed if a decision has already been made to start ...

Treat View Details

FDG-PET Imaging for Hodgkin Lymphoma: Current Use …

Posted: (52 years ago) Moreover, this approach increases patient radiation exposure by 1.5- to 2-fold. 10 At initial staging, FDG-PET/CT is a highly sensitive modality and detects more disease sites than CECT in 25% to 30% of the HL cases. 3-9 Several studies have reported that the sensitivity of FDG-PET/CT is superior to CECT for both nodal disease (92% -94% vs 83% ...

Pet View Details

Monitoring Multiple Myeloma – Hematology & Oncology

Posted: (52 years ago) Additionally, PET/CT has been used for the initial staging and treatment monitoring of nonsecretory MM. 51,52 Several studies have demonstrated the higher sensitivity of PET/CT for the detection of focal bone lesions in comparison with conventional radiography. 53,54 PET/CT testing was improved with the introduction of radioactive tracers, such ...

Treat View Details

Imaging of Prostate Cancer With Positron Emission …

Posted: (52 years ago) Similar results were found in a study comparing 68 Ga-PSMA-11 PET/CT with 99m Tc-MDP bone scintigraphy. 79 In this study, 126 patients were imaged with both methods and PSMA-targeted imaging greatly outperformed bone scan, with sensitivities of 98.7% to 100% for 68 Ga-PSMA-11 PET/CT compared with 86.7% to 89.3% for 99m Tc-MDP bone scintigraphy ...

Pet View Details

Highlights in Renal Cell Carcinoma From the Sixteenth ...

Posted: (52 years ago) An open-label, multicenter study evaluated positron emission tomography (PET)/CT with iodine-124 conjugated to girentuximab in patients with clear cell RCC masses that were scheduled for resection. 6 Girentuximab is a chimeric monoclonal antibody that binds to carbonic anhydrase, which is overexpressed in more than 90% of clear cell RCC tumors ...

Pet View Details

Surveillance Scanning in Lymphoma – Hematology & Oncology

Posted: (52 years ago) Early studies typically reported on surveillance using computed tomography (CT), whereas more recent investigations have used positron emission tomography (PET)/CT. In the majority of lymphoma subtypes, imaging with PET/CT is a standard part of …

Pet View Details

CA 19-9 Tumor Marker: Is It Reliable? A Case Report in a ...

Posted: (52 years ago) Erxi Wu, PhD1 Shuang Zhou, BS1 Kruttika Bhat, PhD1 Qingyong Ma, MD, PhD2 1Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota; 2Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China Address correspondence to: Erxi Wu, PhD, Department of Pharmaceutical Sciences, North Dakota Stat…

Pet View Details

Consolidation Therapy After Autologous Stem Cell ...

Posted: (52 years ago) Sep 09, 2016  · Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284-292.

Pet View Details

Polycythemia Vera: From New, Modified Diagnostic Criteria ...

Posted: (52 years ago) PPV-MF and PET-MF appear to have a higher mutational load (JAK2 V617F–mutated and CALR-mutated allele burden) compared with PV and ET, suggesting a role for the accumulation of mutated alleles in the progression to SMF. 41-43 With regard to additional, nondriver mutations, 25% of patients with SMF have been found to harbor a mutation in ASXL1 ...

Pet View Details

Optimal Treatment of Unresectable Stage III Non–Small Cell ...

Posted: (52 years ago) Nov 11, 2016  · PET provides more sensitive disease staging than conventional staging techniques, and is more likely to assign patients to a higher tumor stage. This phenomenon is known as stage migration, and it may offer the perception that an intervention has improved stage-specific survival when in fact it has not.

Pet View Details

Highlights in Advanced Prostate Cancer From the 2021 ...

Posted: (52 years ago) PSMA PET imaging will also likely be used in the castration-resistant setting to select patients for treatment with 177 Lu-PSMA-617. Currently, 2 PSMA PET imaging modalities are FDA-approved (piflufolastat F 18 and Ga 68 PSMA-11), but these approvals are presently limited to men with early-stage disease at diagnosis or recurrence, rather than ...

Treat View Details

Measurement of Circulating Tumor DNA to Guide Management ...

Posted: (52 years ago) 18 F-FDG PET/CT has a very high negative predictive value at the end of treatment. However, some patients with a negative 18 F-FDG PET/CT at the end of treatment will relapse. Furthermore, the role of interim 18 F-FDG PET/CT scans in predicting the outcomes in DLBCL is not well defined because inflammation and tumor necrosis may lead to false ...

Treat View Details

How I Manage Chronic Lymphocytic Leukemia – Hematology ...

Posted: (52 years ago) 2. Falchi L, Keating MJ, Marom EM, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783-2790. 3. Jain P, Hu S, Jabbour E, et al. Disseminated histoplasmosis as pseudo Richter’s transformation in a patient with chronic lymphocytic leukemia.

Pet View Details

The Evolving Understanding of Prognosis in Post–Essential ...

Posted: (52 years ago) Abstract: Myelofibrosis (MF) is the most aggressive of the classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). In some patients with essential thrombocytopenia or polycythemia vera, which are relatively benign MPNs, MF develops as a natural evolution of their disease, resulting in post–essential thrombocythemia myelofibrosis …

Pet View Details

Emerging Role for Local Therapy in Oligometastatic ...

Posted: (52 years ago) The POPSTAR trial was designed to investigate the safety and feasibility of SABR in OMPC. In this study, Siva and colleagues enrolled 21 patients with up to 3 bone metastases on sodium fluoride F 18 PET/CT. Standardized uptake values (SUVs) before SABR and 6 months after SABR were compared.

Pet View Details

The Timing of Molecular Imaging in Prostate Cancer ...

Posted: (52 years ago) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging . 2015;42(2):197-209. Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer ...

Pet View Details

Successful Treatment of Hepatosplenic T-Cell Lymphoma With ...

Posted: (52 years ago) Positron emission tomography (PET) scan obtained on day +85 failed to demonstrate areas of increased metabolic activity. CT scan revealed stable splenomegaly with no evidence of lymphadenopathy. The patient is currently 22 months from time of diagnosis and 18 months post auto-SCT. She has remained in clinical remission.

Pet View Details

Highlights in Hodgkin Lymphoma From the 61st American ...

Posted: (52 years ago) The patients underwent PET at screening, at the end of cycle 2, and at the end of treatment. An interesting finding from this study is that the interim PET scan did not necessarily lead to a change in treatment. At the time of the interim PET analysis, 89% of patients in the brentuximab vedotin arm and 86% of those in the ABVD arm were PET ...

Treat View Details

PSMA PET/CT for Staging and Treatment of Prostate Cancer ...

Posted: (52 years ago) PSMA PET/CT imaging is not readily available in the United States because the radiotracers are not approved by the US Food and Drug Administration (FDA). This approach has the advantage of encouraging high-quality research toward the goal of FDA approval. In some other countries, radiotracers made within a hospital radiopharmacy are less ...

Food View Details

Highlights in Aggressive Non-Hodgkin Lymphoma From the ...

Posted: (52 years ago) Patients with PET-positive bulky disease after 6 cycles of chemotherapy received radiation therapy (39.6 Gy). The planned interim analysis was conducted after 40% of expected results occurred. The results were compared with those from the group of patients in RICOVER-60 who received 6 cycles of R-CHOP every 14 days plus 2 extra doses of ...

Pet View Details

Richter Transformation of Chronic Lymphocytic Leukemia in ...

Posted: (52 years ago) The role of 18F-FDG-PET in detecting Richter’s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor [published online January 23, 2020]. Haematologica. doi: 10.3324/haematol.2019.240564.

Pet View Details

Lymphomatous Meningitis as a Presentation of Non-Hodgkin ...

Posted: (52 years ago) As mentioned above, FDG-PET may provide evidence of extraneural disease not otherwise seen with computed tomography imaging and may demonstrate disease in the CNS not seen with MRI. As in the present case, a window of opportunity for treatment exists, and delay or failure to make the diagnosis in a timely manner may result in fulminant disease ...

Treat View Details

Current Treatment Approaches in Follicular Lymphoma ...

Posted: (52 years ago) PET scans tend to be somewhat more sensitive and accurate than CT scans. A bone marrow evaluation can be performed but is not always essential. H&O What is the prognosis? BK Currently, the average life expectancy after the diagnosis is probably more than 15 years. The precise number of years is unknown because it takes a long time to determine ...

Pet View Details

H&O Literature Review: Brentuximab Vedotin in Relapsed ...

Posted: (52 years ago) Inclusion criteria included documented CD30-positive, measurable disease (≥1.5 cm by CT; PET-positive); an Eastern Cooperative Oncology Group (ECOG) performance status of less than 2; and adequate hematologic, renal, and liver function.

Pet View Details

Letter From the Editor – Hematology & Oncology

Posted: (52 years ago) Interpretation of FDG-PET/CT is now more standardized with the Deauville 5-point scale, and a single node can be used to indicate progressive disease (within certain parameters), rather than the cumbersome need to measure the sum of the product of the perpendicular diameters of 6 nodes, as in the past.

Pet View Details

Highlights in Hodgkin Lymphoma From the 62nd American ...

Posted: (52 years ago) PET positivity after cycle 2 and cycle 4 was used to stratify patients, revealing 3 statistically significant different subsets for predicting PFS (P

Pet View Details

Is Maintenance Therapy Necessary in Low-Grade Lymphoma ...

Posted: (52 years ago) The first trials that attempted to evaluate the utility of maintenance rituximab included different induction regimens—generally not including rituximab—followed by varying maintenance schedules. The Swiss Group for Clinical Cancer Research led the first study, SAKK 35/98, in which patients with follicular lymphoma received rituximab for 4 weeks, followed by either obse…

Pet View Details

Hodgkin Lymphoma in Pregnancy: A Case Report – Hematology ...

Posted: (52 years ago) PET/CT should be performed after delivery to assess treatment response. Staging of a pregnant patient with HL should be based on history, physical examination, routine blood tests, and bone marrow biopsies, as well as on MRI or ultrasonography, which can be useful alternatives to CT. 6,7 There was no adverse birth outcome, with the exception of ...

Treat View Details

Advances in Aggressive Lymphoma From the 2018 American ...

Posted: (52 years ago) PET may be a better tool to stratify patients for further therapy. Indeed, the OPTIMAL >60 study (Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine) in elderly patients with DLBCL, conducted by the same group, suggested that radiotherapy can be avoided in end-of-treatment PET ...

Treat View Details

The Current Status of Secondary Cytoreduction in Ovarian ...

Posted: (52 years ago) A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75(3-4):152-158. 27. Fanfani F, Monterossi G, Fagotti A, et al. Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.

Treat View Details

Relapsed Diffuse Large B-Cell Lymphoma–10 Years Later ...

Posted: (52 years ago) Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), and it accounts for approximately 25% of NHL cases. 1 The incidence of DLBCL in the United States is approximately 7 cases per 100,000 person-years, with a male predominance. 2 Caucasian Americans have higher rates than African Americans, Asians, and ...

Pet View Details

Highlights in Lymphoma From the 12th International ...

Posted: (52 years ago) Sep 14, 2013  · Reports suggest that interim PET/ CT scans after 2 cycles of ABVD are highly predictive of treatment failure with ABVD. 3 Patients who were PET-positive after 2 cycles of ABVD have a chance of achieving PFS of 10% to 15%, compared with perhaps 90% if they are PET-negative. This finding suggested an opportunity for early dose escalation in PET ...

Treat View Details

Abnormal Partial Thromboplastin Time in Adults and ...

Posted: (52 years ago) Rajiv K. Pruthi, MBBS. Associate Professor of Medicine Mayo Clinic Rochester, Minnesota. H&O What is the partial thromboplastin time (PTT) test?. RP The coagulation cascade consists of 3 pathways, an extrinsic pathway and an intrinsic pathway, which converge on a final common pathway.There are multiple clotting factors in all 3 pathways, and the PTT test measures the …

Pet View Details

Posterior Reversible Encephalopathy Syndrome – Hematology ...

Posted: (52 years ago) A positron emission tomography (PET)/computed tomography (CT) scan revealed extensive osseous lesions consistent with malignancy. She was started on anastrozole (Arimidex, AstraZeneca) 1 mg daily and zoledronic acid 4 mg once monthly in November 2008. Anastrozole was discontinued in June 2009 due to disease progression, and the patient’s ...

Pet View Details

Highlights in B-Cell Malignancies From the 61st American ...

Posted: (52 years ago) Of the 59 PET-positive patients, 55 received radiotherapy, 2 received 3 additional cycles of R-CHOP, and 2 patients received 1 additional cycle of R-CHOP. After a median follow-up of 6.25 years, 21 of 254 PET-negative patients (8%) relapsed, compared with 13 …

Pet View Details

Risk Stratification in Multiple Myeloma, Part 1 ...

Posted: (52 years ago) In another study by the University of Arkansas group, the prognostic value of FDG-PET and MRI was compared in 239 patients who received a Total Therapy regimen. 16 In multivariate analysis, FDG-PET at diagnosis was the only imaging modality significantly associated with inferior OS and event-free survival (EFS). The 30-month estimate of OS for ...

Pet View Details

Refining the Management of Relapsed or Refractory ...

Posted: (52 years ago) Radiographic surveillance, typically performed with CT scans or occasionally PET scans, tend to be administered more frequently soon after completion of frontline or subsequent therapy, and become less frequent with time. In cases of long-term remission, radiographic surveillance is superseded by clinical surveillance.

Pet View Details

First-Line Use of Novel Hormonal Agents in Prostate Cancer ...

Posted: (52 years ago) Therefore, the outcomes of patients with tumor progression—defined by positron emission tomography (PET) or the measurement of prostate-specific antigen (PSA) levels—treated in the modern era with newer agents may appear to be better than the outcomes of patients treated with older agents, when in fact the older agents were targeting more ...

Treat View Details

Contemporary Management of the Axilla in Breast Cancer ...

Posted: (52 years ago) 14. Cooper KL, Meng Y, Harnan S, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. …

Pet View Details

Multiple Myeloma With Multiple Extramedullary ...

Posted: (52 years ago) Multiple myeloma (MM) is a neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Active MM is defined by the presence of an M-protein in the serum or urine, plasma cell infiltration of the bone marrow (at least 10%), and the presence of related tissue or organ impairment.

Pet View Details

Highlights in CAR T-Cell Therapy From the 62nd American ...

Posted: (52 years ago) All patients received 2 cycles of up-front chemoimmunotherapy, and then underwent restaging based on the results of a positron emission tomography (PET) scan. Patients without a complete response after 2 cycles of therapy received axicabtagene ciloleucel at that point, which was considered to be the first-line setting.

Pet View Details